Sasanlimab

Sasanlimab binds with high affinity to human and cynomolgus monkey PD-1, and shows no detectable binding to rat PD-1^[2].
Sasanlimab (1 h) binds with high affinity to cell surface-expressed human and cynomolgus monkey PD-1 (EC₅₀ values 51.04-222.55 pM across primary and transfected T cell models), shows minimal binding to mouse PD-1, and no detectable binding to rat PD-1^[2].
Sasanlimab (serial dilutions, pmol/L range; 1 h) potently blocks the interaction of cell surface-expressed human and cynomolgus monkey PD-1 with their ligands PD-L1 and PD-L2, with IC₅₀ values ranging from 839-1,058 pM^[2].
Sasanlimab reverses PD-1/PD-L1-mediated inhibition of NFAT signaling in human PD-1-expressing Jurkat T cells, with an IC₅₀ of 0.33 μg/mL^[2].
Sasanlimab (10^-5-10¹ μg/mL; 5 days) dose-dependently enhances human T-cell proliferation and production of IFNγ, TNFα, and IL2 in mixed lymphocyte reaction assays with PD-L1-expressing cells^[2].
Sasanlimab (0.01-100 μg/mL; 1 h) dose-dependently enhances SEB-induced production of IFNγ, TNFα, and IL2 in cynomolgus monkey whole blood^[2].
Sasanlimab does not mediate significant antibody-dependent cell-mediated cytotoxicity against activated human T cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.